Lauren Biscaldi, MS

Investigators analyzed the proportion of individuals with 1 of 3 clusters of Long COVID symptoms.

The new medication reduces HbA1c and improves glycemic control as an adjunct to diet and exercise.

New legislation removes what many perceived as a barrier to treating opioid use disorder.

The PDUFA date has been set for May 22, 2023.

The updates include new recommendations for COVID-19 and pneumococcal vaccines.

Moderna’s mRNA-1345 vaccine targets RSV in older adults.

Take a look back at the top 15 articles that we published in 2022.

Your weekly roundup of the latest news from Drug Topics®.

Lenacapavir was approved with the FDA's Breakthrough Therapy Designation.

Stay on the nice list with these tips to help stop the spread of winter respiratory viruses.

Biosimilar medications stand to significantly increase cost savings for patients.

Job satisfaction is down and workplace stress is on the rise.

New pathways of care are needed to improve health care spending.

Study participants experienced better outcomes vs standard of care with a digital inhaler system.

Investigators set out to evaluate how medication access for certain rheumatic conditions has changed since June 2022.

Cost savings were not associated with an increase in adverse drug events.

Low-income subsidies can eliminate much of the out-of-pocket costs that patients must pay.

Pharmacists can optimize medication adherence and serve as an additional touchpoint for patients during treatment.

Two clinical pathways were created to manage patients and required resources.

Developing more advanced roles for pharmacy technician can reduce turnover in roles.

Providing culturally competent care is one way pharmacists can help improve vaccine uptake in their communities.

Immunocompromised adults aged 19 years or older are eligible to receive the recombinant zoster vaccine.

The COVID-19 pandemic disrupted routine immunization programs around the world.

CVS is the first pharmacy to offer this service nationwide.

Insulin glargine-aglr received initial FDA approval in December 2021.

Timing of treatment initiation is crucial for patients with cancer.

CBD therapy has had positive outcomes in other inflammatory conditions.

Results of multiple studies were presented at IDWeek 2022.

Investigators reviewed data from 19 studies and 11 consecutive flu seasons.